Allena Pharmaceuticals
Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders
Based in MA
AI Overview
With $90K in lobbying spend across 5 quarterly filings, Allena Pharmaceuticals is an active lobbying client. Their lobbying covers 3 issue areas. Active from 2019 to 2020.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2019 | $90K |
| 2020 | $0 |
Issues Lobbied
Lobbying Firms
Lobbyists
Government Agencies Targeted
These are the government entities that Allena Pharmaceuticals disclosed contacting in their lobbying filings.
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues, Medicare/Medicaid, MED
Advancing American Kidney Health Initiative
National Kidney Initiative -- Development of first in class therapeutics for patients with
rare and severe metabolic disorders that affect the kidney.
Related Analysis
Related Investigations
Similar Clients
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.